New apalutamide study opens for prostate cancer

February 14, 2018

A new phase 3 study at Providence Cancer Institute will compare the effectiveness of three different treatment regimens in men with biochemically recurrent prostate cancer:

Experimental arm: apalutamide, an investigational, next-generation oral androgen receptor (AR) inhibitor, plus degarelix, a hormonal therapy used to reduce testosterone
Experimental arm: apalutamide and degarelix plus abiraterone acetate and prednisone
Control arm: degarelix alone

“Apalutamide (ARN-509) reduced the risk of metastasis or death by 72% in patients with nonmetastatic castration-resistant prostate cancer,” according to findings from the phase 3 SPARTAN trial reported in OncLive on Feb. 5. The SPARTAN trial, published in the New England Journal of Medicine on Feb. 8, found that “median metastasis-free survival was more than 2 years longer” for men who received apalutamide. Read more in the New York Times.

Brendan Curti, M.D., the principal investigator of the new three-arm study at Providence Cancer Institute, is a medical oncologist and director of genitourinary oncology research at the Earle A. Chiles Research Institute.

See Providence study details here:

A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

More prostate cancer studies

This study is one of three clinical trials open to men with prostate cancer at Providence Cancer Institute. See all prostate cancer studies.

To refer patients to any of these studies, call Providence Cancer Institute’s Clinical Research office at 503-215-2614 or visit oregon.providence.org/clinical-trials.

Welcome to your journey for creating a healthier you

New apalutamide study opens for prostate cancer

See Providence study details here:

More prostate cancer studies

Previous Article

Next Article

New apalutamide study opens for prostate cancer

See Providence study details here:

More prostate cancer studies

Previous Article

Next Article

Most Recent Articles

Back pain is among the most common and debilitating conditions, capable of hindering our mobility, disrupting our daily activities and diminishing our quality of life.

The hospital was among 16 organizations celebrated for transforming healthcare delivery across Partnership Health Plan’s 24-county service region.

ncy medical care in the community.” Queen of the Valley Medical Center’s level III trauma center and emergency department will remain open 24/7/365 throughout the renovations.

https://www.youtube.com/watch?v=BtIJsq7J--w

Providence Alaska Children’s Hospital formally dedicated the Panda Cares Center of Hope during a celebration event on Friday, June 20.

Providence Saint Joseph Medical Center in Burbank, Calif., has earned its second Magnet® recognition, a prestigious honor bestowed by the American Nurses Credentialing Center.

Providence Alaska Chief Executive Ella Goss, MSN, RN, has announced her retirement as chief executive of Providence Alaska, the state’s largest health care provider, beginning Aug. 1.

Now is the time to stand up for those who rely on Medicaid as a lifeline and safety net.

Providence Queen of the Valley Medical Center is honored to have received the CalAIM Make a Difference Award from Partnership HealthPlan of California for advancing innovative and holistic health care

When Janet was diagnosed with breast cancer, she knew she wouldn't be able to afford treatment. But thanks to Medicaid, she was able to get the life-saving treatment she needed.

In 2024, Providence contributed $188 million to programs, charity care, unpaid costs of Medicare and Medi-Cal across Northern California according to the Annual Report to Our Communities, published on

A generous gift of plush blankets helps comfort patients during their chemotherapy treatments at Providence Cancer Institute Newberg Clinic.

Magnet® designation is considered gold standard for nursing excellence

St. Mary security officers on patrol carrying Narcan for opioid overdoses

Providence Santa Rosa Memorial Hospital is pleased to announce the appointment of Kendra Crawford, MS, BSN, RN, CPHQ, NEA-BC, FACHE, as the new chief nursing officer.

Hospital caregivers enjoyed a fun surprise last week when cast members from the Max Original medical drama “The Pitt” stopped by for a visit.

In partnership with the American Heart Association, the training kiosk will travel to multiple LA locations to teach lifesaving skills.

Prioritize your skin health with these expert tips.